Guaraná for Radiation Related Fatigue in Breast Cancer Patients
Primary Purpose
Fatigue
Status
Completed
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
Guaraná
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Fatigue
Eligibility Criteria
Inclusion Criteria:
- histological diagnosis of early stage Breast Cancer
- 18 years old or older
Exclusion Criteria:
- prior breast radiation
- anemia
- clinical depression
- unable to sign informed consent
Sites / Locations
- Faculdade de Medicina do ABC
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
A
B
Arm Description
Outcomes
Primary Outcome Measures
Fatigue
Secondary Outcome Measures
Depression
Full Information
NCT ID
NCT00615316
First Posted
February 4, 2008
Last Updated
February 13, 2008
Sponsor
Faculdade de Medicina do ABC
1. Study Identification
Unique Protocol Identification Number
NCT00615316
Brief Title
Guaraná for Radiation Related Fatigue in Breast Cancer Patients
Official Title
Guaraná ("Paullinia Cupana") for Radiation Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2008
Overall Recruitment Status
Completed
Study Start Date
December 2006 (undefined)
Primary Completion Date
June 2007 (Actual)
Study Completion Date
June 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Faculdade de Medicina do ABC
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
We hypothesize that Guaraná, a native plant from the Amazon, might improve radiation-induced fatigue in breast cancer patients undergoing treatment. In order to assess this, we randomized patients to either guaraná extract or to placebo, switching the assigned treatment mid-term through the radiation.
Detailed Description
The aim of this study is evaluate the favourable effects of Guaraná in memory and cognition in humans After approval by our Institutional Review Board, we included consenting patients with a histological diagnosis of early stage Breast Cancer for whom adjuvant radiation therapy was indicated. We excluded patients with a previous history of Radiation Therapy, anemia or clinical depression. We also excluded patients who were unable to grant informed consent or those who had medical contraindindications for the use of Guaraná (because of its psycho stimulant effect) such as uncontrolled hypertension, previous history of cardiac arrhythmia and insomnia.
The radiation therapy for patients who underwent mastectomy consisted of 28 fractions of 180cGy.
This study had a double-blind randomized design with crossover between experimental arms. After getting informed consent, we randomized patients at the beginning of radiation treatments (Phase I) to either 75 mg of Guaraná extract daily (Group A) or to Placebo (Group B). Randomization was centralized by the pharmacist. Halfway through the radiation treatments (Phase II), we switched patients from placebo to guaraná and vice versa. The protocol ended at the last session of radiation treatments (Phase III). In each of these three phases a new assessment of fatigue and depressive symptoms was undertaken, ie: immediately before the first radiation treatment (phase I); at switching (phase II) and right before the start of the last radiation treatment (phase III). At these three assessment points, patients had to complete the Chalder Fatigue Scale,4 the MD Anderson Brief Fatigue Inventory (available at http://www.mdanderson.org/topics/fatigue/) available in Portuguese, and the Beck Inventory Depression Scale II also validated in Portuguese.
We conducted the statistical analysis of the data with the Numerical Control Software Solution (www.ncss.com). We employed the repeated measures analysis of variance (ANOVA) test to compare tests scores within the same patient group and the ANOVA test to compare test's scores between the two groups (at similar phases of the study).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fatigue
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A
Arm Type
Experimental
Arm Title
B
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Guaraná
Other Intervention Name(s)
Paullinia Cupana
Intervention Description
Guaraná extract 75mg/day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo 1tab/d
Primary Outcome Measure Information:
Title
Fatigue
Time Frame
5 weeks
Secondary Outcome Measure Information:
Title
Depression
Time Frame
5 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
histological diagnosis of early stage Breast Cancer
18 years old or older
Exclusion Criteria:
prior breast radiation
anemia
clinical depression
unable to sign informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Auro Del Giglio, MD, PhD
Organizational Affiliation
ABC Foundation School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Faculdade de Medicina do ABC
City
Santo André
State/Province
São Paulo
ZIP/Postal Code
09060-650
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Guaraná for Radiation Related Fatigue in Breast Cancer Patients
We'll reach out to this number within 24 hrs